Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide Monotherapy vs Placebo in Chinese T2DM (PIONEER 11)
NCT04109547Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04109547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109547.